| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $67.04 | $14.25B | N/A |
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe
http://www.zacks.com/stock/news/322513/mercks-keytruda-combo-gets-nod-for-lung-cancer-in-europe?cid=CS-ZC-FT-322513
Sep 11, 2018 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
0
Merck's Keytruda Gets Priority Review for Rare Skin Cancer
http://www.zacks.com/stock/news/321571/mercks-keytruda-gets-priority-review-for-rare-skin-cancer?cid=CS-ZC-FT-321571
Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
0
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
http://www.zacks.com/stock/news/317485/agenus-agen-q2-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-317485
Aug 10, 2018 - Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
0
The 3 Worst Healthcare Stocks of 2018 (So Far)
https://www.fool.com/investing/2018/07/19/the-3-worst-healthcare-stocks-of-2018-so-far.aspx?source=iedfolrf0000001
Jul 19, 2018 - Find out how three companies have lost their shareholders a combined $31 billion so far this year.
0
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
http://www.zacks.com/stock/news/312300/cti-biopharma-tanks-post-type-b-talks-on-pacritinib-with-fda?cid=CS-ZC-FT-312300
Jul 19, 2018 - CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
0
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
http://www.zacks.com/stock/news/312213/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2?cid=CS-ZC-FT-312213
Jul 19, 2018 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
0
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
http://www.zacks.com/stock/news/310183/mercks-keytruda-gets-priority-review-in-difficult-lung-cancer?cid=CS-ZC-FT-310183
Jul 03, 2018 - Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
0
Better Know Biotech: 2 Stocks You've Got to Know About
https://www.fool.com/investing/2018/06/01/better-know-biotech-2-stocks-you-better-know-about.aspx?source=iedfolrf0000001
Jun 01, 2018 - These two small-cap biotech stocks could be about to make it big.
0
Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue?
http://www.zacks.com/stock/news/305890/incyte-incy-up-102-since-earnings-report-can-it-continue?cid=CS-ZC-FT-305890
May 31, 2018 - Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
3 Biotechs With Huge FDA Decisions in June
https://www.fool.com/investing/2018/05/31/3-biotechs-with-huge-fda-decisions-in-june.aspx?source=iedfolrf0000001
May 31, 2018 - The clock is ticking for these biotechs hoping to score key regulatory victories.
0